A Pilot, 4-Week, Randomized, Double-Blind, Placebo-Controlled, Inpatient, Multicenter Study of the Safety, Population Pharmacokinetics, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
Latest Information Update: 27 Apr 2022
At a glance
- Drugs SP 624 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Sirtsei Pharmaceuticals
- 10 Aug 2021 Status changed from active, no longer recruiting to completed.
- 22 Feb 2021 Planned End Date changed from 1 May 2021 to 1 Apr 2021.
- 22 Feb 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Mar 2021.